Академический Документы
Профессиональный Документы
Культура Документы
Nitin Gupta
Intellectual Property
“Intellectual Property is the Property, which has
been created by exercise of Intellectual Faculty”
• Patent
• Industrial Design
• Trademark
• Copyright
• Geographical Indication
• Layout design of industrial circuits
Patent
• Set of exclusive rights
– Given to the inventor
– By the state
– For a fixed period of time
• Examples
– Art
– Software
Another way to protect your creation
And one more,
if you are an emperor
Money Industry Patents
Indian Patent Office
• Administered by
– ~300 examiners
– Headoffice Kolkata
8000
7000
Number of Applications
6000
5000
Domestic
Foreign
4000
3000
2000
1000
0
19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19 19
70- 75- 80- 84- 85- 86- 87- 98- 89- 90- 91- 92- 93- 94- 95- 96- 97- 98-
71 76 81 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99
Year
• A patent is valid if
– satisfies common requirements
– not proven invalid
Patent Opposition
• Pre-grant Opposition
– Patent applications are published
– Non-compliance
– Non/wrong-disclosure
• Post-grant Opposition
– Within 12 months of grant of a patent
– Misconduct, public display, non-patentable
Patent Infringement
• Atomic energy
• Traditional knowledge
• Scientific principle
• Abstract theory
• Discovery of natural substances
• New form of a known substance
• Mixture of known compounds
• Methods of agriculture
History of Indian Patent System
1856 The Act of 1856 on protection of invention
http://ipindia.nic.in/ipr/patent/history.htm
TRIPS
• Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS)
• WTO
• Formulated 1986-1994
Only process not product patents in food, Process and product patents in almost all fields
medicines, chemicals of technology
Government allowed to use patented invention Very limited scope for governments to use
to prevent scarcity patented inventions
How TRIPS came into being
• Until 1989, India opposed IPR policies in GATT
160
140
120
100
80
170
60 146
40
86
20 49
24 32
0
1999 2000 2001 2002 2003 2004
Effect on Patients
No Generics
availability affected
AIDS
• Gilead: Tenofovir
– $5718 / patient / year
• Cipla: Tenvir
– $ 700 / patient / year
– Plans to make available for $350 in Africa
• In 2005, Patent amendment prohibits minor variants – In 2006, Novartis lost the rights